A Red Mitochondria-Targeted AIEgen for Visualizing H2S in Living Cells and Tumours - Analyst (RSC Publishing)

Hydrogen sulfide (H2S) exits in the cytosols and mitochondria of mammalian cells as a signaling molecule. The scientists have explored many important physiological functions of H2S, such as regulating vasodilator relaxation, protecting living cells avoiding damage. The measurement for H2S is necessary to explore in biological function of cells and tissues. Herein, we design and synthesize a new aggregation-induced emission luminogen (AIEgen) with more extent conjugate and more positive charge based on the previous research about the mitochondrial-targeted luminogens. The Indo-TPE-Indo can enter cells rapidly compared with only one indolium AIEgen (TPE-indo), and recognize HS- selectively in mitochondrion with the nucleophilic reaction of indolium and HS-. The linear range (1-100 μM) of sensing HS- can satisfy the requirement of HS- concentration in living cells and tumors. The article wasreceived on 28 Feb 2019,accepted on 31 Mar 2019andfirst published on 02 Apr 2019 If you are not the author of this article and you wish to reproduce material from it in a third party non-RSC publication you mustformally request permission using Copyright Clearance Center. Go to ourInstructions for using Copyright Clearance Center page for details. Authors contributing to RSC publications (journal articles, books or book chapters) do not need to formally request permission to reproduce material contained in this article provided that the correct acknowledgement is given with the reproduced material. Reproduced material should be attributed as follows: For reproduction of material from NJC: Reproduced from Ref. XX with permission from the Centre National de la Recherche Scientifique (CNRS) and The Royal Society of Chemistry. For reproduction of material from PCCP: Reproduced from Ref. XX with permission from the PCCP Owner Societies. For reproduction of material from PPS: Reproduced from Ref. XX with permission from the European Society for Photobiology, the European Photochemistry Association, and The Royal Society of Chemistry. For reproduction of material from all other RSC journals and books: Reproduced from Ref. XX with permission from The Royal Society of Chemistry. If the material has been adapted instead of reproduced from the original RSC publication "Reproduced from" can be substituted with "Adapted from". In all cases the Ref. XX is the XXth reference in the list of references. If you are the author of this article you do not need to formally request permission to reproduce figures, diagrams etc. contained in this article in third party publications or in a thesis or dissertation provided that the correct acknowledgement is given with the reproduced material. Reproduced material should be attributed as follows: For reproduction of material from NJC: [Original citation] - Reproduced by permission of The Royal Society of Chemistry (RSC) on behalf of the Centre National de la Recherche Scientifique (CNRS) and the RSC For reproduction of material from PCCP: [Original citation] - Reproduced by permission of the PCCP Owner Societies For reproduction of material from PPS: [Original citation] - Reproduced by permission of The Royal Society of Chemistry (RSC) on behalf of the European Society for Photobiology, the European Photochemistry Association, and RSC For reproduction of material from all other RSC journals: [Original citation] - Reproduced by permission of The Royal Society of Chemistry If you are the author of this article you still need to obtain permission to reproduce the whole article in a third party publication with the exception of reproduction of the whole article in a thesis or dissertation. Information about reproducing material from RSC articles with different licences is available on our Permission Requests page.



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More